Ming Lei
About Ming Lei
Ming Lei is the Scientific Director at Bristol Myers Squibb with extensive experience in cancer biology and immuno-oncology.
Current Position at Bristol Myers Squibb
Ming Lei serves as the Scientific Director at Bristol Myers Squibb. In this role, he is involved in leading scientific research and development efforts, guiding preclinical and translational studies to support drug development, and contributing to the advancement of clinical trials. His work notably focuses on both solid tumors and hematological malignancies, underpinned by his extensive experience in these areas.
Professional Experience at Celgene Corporation
Before joining Bristol Myers Squibb, Ming Lei worked at Celgene Corporation as Scientist II from 2014 to 2016. During his tenure, he was engaged in designing and executing preclinical and translational studies. His contributions were vital in supporting the development stages of various drug candidates, particularly in the realm of immunomodulatory drugs.
Academic Background and Education
Ming Lei holds a Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology from Harvard University. He also earned a Bachelor's Degree in Biological Sciences from Peking University. His educational background provided him with a strong foundation in cancer biology, immuno-oncology, cell biology, stem cells, and mouse models, which have been significant assets in his professional career.
Experience at Columbia University Medical Center
From 2008 to 2014, Ming Lei served as an Associate Research Scientist at Columbia University Medical Center. Over six years, he developed and honed his problem-solving, multi-tasking, communication, and interpersonal skills. His work primarily revolved around complex research areas in cancer biology and translational medicine.
Contributions to Rheumatology and Immunology Research
Ming Lei has over 20 years of experience in rheumatology research and is actively involved in educational resources and community partnerships to enhance care in rheumatic diseases. His innovative research spans gastrointestinal immune-mediated diseases, dermatologic immune-mediated diseases, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis. Additionally, he is part of the team at the Thomas O. Daniel Research Incubator and Collaboration Center, where he supports early entrepreneurial biotech companies.